메뉴 건너뛰기




Volumn 42, Issue 6, 2008, Pages 607-615

A noninferiority margin for acne lesion counts

Author keywords

Acne; Active control; Choice of delta; Noniferiority margin

Indexed keywords

AZELAIC ACID; DIANE; DIENOGEST PLUS ETHINYLESTRADIOL; DROSPIRENONE PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; FINACEA; UNCLASSIFIED DRUG;

EID: 57449087983     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150804200608     Document Type: Article
Times cited : (10)

References (19)
  • 1
    • 16444379380 scopus 로고    scopus 로고
    • Clinical practice: Acne
    • James WD. Clinical practice: acne. N Engl J Med. 2005;352:1463-1472.
    • (2005) N Engl J Med , vol.352 , pp. 1463-1472
    • James, W.D.1
  • 2
    • 57449095601 scopus 로고    scopus 로고
    • Center for Drug Evaluation and Research. Clinical/ medical guidance for industry acne vulgaris: developing drugs for treatment. September, Available at:, accessed January 16, 2007
    • US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Clinical/ medical guidance for industry acne vulgaris: developing drugs for treatment. September 2005. Available at: http://www.fda.gov/cder/ guidance/6499dft.pdf, accessed January 16, 2007.
    • (2005)
  • 4
    • 57449111854 scopus 로고    scopus 로고
    • Committee for Medicinal Products for Human Use. Guideline on the Choice of the Non-Inferiority Margin. London, July 27, 2005. Doc. Ref. EMEA/ CPMP/EWP/2158/99. Available at: http://www.emea.eu.int/pdfs/human/ewp/ 215899en.pdf, accessed October 31, 2005.
    • Committee for Medicinal Products for Human Use. Guideline on the Choice of the Non-Inferiority Margin. London, July 27, 2005. Doc. Ref. EMEA/ CPMP/EWP/2158/99. Available at: http://www.emea.eu.int/pdfs/human/ewp/ 215899en.pdf, accessed October 31, 2005.
  • 5
    • 0017360990 scopus 로고
    • The measurement of observer agreement for categorical data
    • Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174.
    • (1977) Biometrics , vol.33 , Issue.1 , pp. 159-174
    • Landis, J.R.1    Koch, G.G.2
  • 6
    • 8744296509 scopus 로고    scopus 로고
    • SAS Institute Inc, Cary, NC: SAS Institute Inc
    • SAS Institute Inc. 2004. SAS/STAT® 9.1 User's Guide. Cary, NC: SAS Institute Inc.
    • (2004) SAS/STAT® 9.1 User's Guide
  • 7
    • 57449105859 scopus 로고    scopus 로고
    • Available at
    • SAS Institute Inc. Available at: www.sas.com.
  • 8
    • 57449120047 scopus 로고    scopus 로고
    • Scale development for clinical assessment
    • Schwindt AD, Maibaich HI, eds, New York: Kluwer;
    • Schmitt GJ. Scale development for clinical assessment. In: Schwindt AD, Maibaich HI, eds. Cutaneous Biometrics. New York: Kluwer; 2000.
    • (2000) Cutaneous Biometrics
    • Schmitt, G.J.1
  • 9
    • 57449116301 scopus 로고    scopus 로고
    • Double-blind, randomized, multicenter study with SH T 470 FA in comparison with Diane®-35 in women with acne over 9 treatment cycles
    • number AM80, June 18, 1998
    • Loock W. Double-blind, randomized, multicenter study with SH T 470 FA in comparison with Diane®-35 in women with acne over 9 treatment cycles. Schering AG internal research report number AM80, June 18, 1998.
    • Schering AG internal research report
    • Loock, W.1
  • 10
    • 0036547728 scopus 로고    scopus 로고
    • The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea
    • van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis. 2002;69(4 Suppl):2-15.
    • (2002) Cutis , vol.69 , Issue.4 SUPPL. , pp. 2-15
    • van Vloten, W.A.1    van Haselen, C.W.2    van Zuuren, E.J.3    Gerlinger, C.4    Heithecker, R.5
  • 11
    • 8644247663 scopus 로고    scopus 로고
    • Assessing the relationship between investigator global evaluation and acne lesion counts
    • Alosh M, Wilkin J. Assessing the relationship between investigator global evaluation and acne lesion counts. Drug Inf J. 2004;38:343-351.
    • (2004) Drug Inf J , vol.38 , pp. 343-351
    • Alosh, M.1    Wilkin, J.2
  • 12
    • 0030693350 scopus 로고    scopus 로고
    • Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris
    • Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37:746-754.
    • (1997) J Am Acad Dermatol , vol.37 , pp. 746-754
    • Lucky, A.W.1    Henderson, T.A.2    Olson, W.H.3
  • 13
    • 0031127746 scopus 로고    scopus 로고
    • Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: A randomized, placebo-controlled trial
    • Redmond GP, Olson WH, Lippman JS, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89: 615-622.
    • (1997) Obstet Gynecol , vol.89 , pp. 615-622
    • Redmond, G.P.1    Olson, W.H.2    Lippman, J.S.3
  • 14
    • 57449097745 scopus 로고    scopus 로고
    • Multicenter, double-blind, randomized parallel group study on efficacy of 0.03 mg ethinylestradiol and 2 mg dienogest in comparison to triphasic ethinylestradiol and norgestimate over six cycles in patients with acne papulopustulosa
    • June 21
    • Bongartz M. Multicenter, double-blind, randomized parallel group study on efficacy of 0.03 mg ethinylestradiol and 2 mg dienogest in comparison to triphasic ethinylestradiol and norgestimate over six cycles in patients with acne papulopustulosa. Schering AG internal clinical study report number A07062, June 21, 2002.
    • (2002) Schering AG internal clinical study report , Issue.A07062
    • Bongartz, M.1
  • 15
    • 57449091675 scopus 로고    scopus 로고
    • Multicenter, double-blind, randomized parallel group study on efficacy of 0.03 mg ethinylestradiol and 3 mg drospirenone (DRSP) in comparison to triphasic ethinylestradiol and norgestimate (NGM) over six cycles in patients with mild to moderate acne papulopustulosa
    • February 25, as amended
    • Wack C. Multicenter, double-blind, randomized parallel group study on efficacy of 0.03 mg ethinylestradiol and 3 mg drospirenone (DRSP) in comparison to triphasic ethinylestradiol and norgestimate (NGM) over six cycles in patients with mild to moderate acne papulopustulosa. Schering AG internal clinical study report number A07148, February 25, 2003, as amended.
    • (2003) Schering AG internal clinical study report , Issue.A07148
    • Wack, C.1
  • 16
    • 57449091861 scopus 로고    scopus 로고
    • Schneider A. Multicenter, double-blind, randomized parallel group study on efficacy of 0.035 mg ethinylestradiol/2 mg cyproterone acetate and of 0.035 mg ethinylestradiol/2 mg cyproterone acetate in combination with 10 mg cyproterone acetate in comparison to triphasic ethinylestradiol/ norgestimate over 6 cycles in women with acne papulopustulosa. Schering AG internal clinical study report number A18566, July 2, 2004.
    • Schneider A. Multicenter, double-blind, randomized parallel group study on efficacy of 0.035 mg ethinylestradiol/2 mg cyproterone acetate and of 0.035 mg ethinylestradiol/2 mg cyproterone acetate in combination with 10 mg cyproterone acetate in comparison to triphasic ethinylestradiol/ norgestimate over 6 cycles in women with acne papulopustulosa. Schering AG internal clinical study report number A18566, July 2, 2004.
  • 18
    • 57449103309 scopus 로고    scopus 로고
    • A 12-week, randomized, double-blind multicenter study comparing the clinical efficacy and safety of azelaic acid 15% gel (SH H 655 BA) with its vehicle (SH H 655 PBA) in patients with mild to moderate acne. Berlex Inc. internal clinical study report number A09242, September 16, 2004.
    • A 12-week, randomized, double-blind multicenter study comparing the clinical efficacy and safety of azelaic acid 15% gel (SH H 655 BA) with its vehicle (SH H 655 PBA) in patients with mild to moderate acne. Berlex Inc. internal clinical study report number A09242, September 16, 2004.
  • 19
    • 57449100225 scopus 로고    scopus 로고
    • Gaupe K. An 8-week controlled, double-blind pilot study comparing the initial clinical effect of 15% azelaic acid hydrogel SH H 655 BA with 20% azelaic acid cream (Skinoren®) during twice-daily topical treatment of patients with papulopustular facial acne. Schering AG internal clinical study report number AU36, January 15, 1999.
    • Gaupe K. An 8-week controlled, double-blind pilot study comparing the initial clinical effect of 15% azelaic acid hydrogel SH H 655 BA with 20% azelaic acid cream (Skinoren®) during twice-daily topical treatment of patients with papulopustular facial acne. Schering AG internal clinical study report number AU36, January 15, 1999.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.